Review

The Microbiota–Gut–Brain Axis in Disorders of Gut–Brain Interaction: Mechanisms and Emerging Therapeutic Strategies

Volume 37 · Issue 11 Publish Date: September 15, 2026
Full Text PDF
DOI
Cong Yu ORCID
Department of Gastroenterology, Qingdao Hospital, University of Health and Rehabilitation Sciences (Qingdao Municipal Hospital), Qingdao, China
Xiu Wang ORCID
Department of Obstetrics, Qingdao Hospital, University of Health and Rehabilitation Sciences (Qingdao Municipal Hospital), Qingdao, China
Shuzhu Chen ORCID
Department of Gastroenterology, Qingdao Hospital, University of Health and Rehabilitation Sciences (Qingdao Municipal Hospital), Qingdao, China
Yu, C., Wang, X., & Chen, S. (2026). The Microbiota–Gut–Brain Axis in Disorders of Gut–Brain Interaction: Mechanisms and Emerging Therapeutic Strategies. Turkish Journal of Gastroenterology, 37(11), 1115–1129. https://doi.org/10.5152/tjg.2026.25517
Full Text Full Text PDF

Abstract

Disorders of gut–brain interaction (DGBIs), traditionally termed functional gastrointestinal disorders, affect approximately 15% of adults worldwide and are characterized by chronic digestive symptoms without identifiable structural abnormalities. According to the recently updated Rome V framework, DGBIs are characterized by pathogenic dysregulation of bidirectional communication among the central nervous system, enteric nervous system, and intestinal microbiota. This review examines the anatomical and molecular foundations of gut–brain axis (GBA) communication, emphasizing the roles of microbial metabolites (e.g., short-chain fatty acids and tryptophan derivatives) in neuroimmune modulation and visceral sensitivity. The authors analyze GBA dysfunction across major DGBIs subtypes (irritable bowel syndrome, functional dyspepsia, and functional abdominal pain syndrome), highlighting microbiota dysbiosis, barrier dysfunction, and central sensitization. Current therapies include psychological interventions, neuromodulation, microbiota-targeted approaches, dietary management, and pharmacotherapy; however, treatment responses remain highly heterogeneous across patient populations, highlighting the potential value of biomarker-guided and mechanism based therapeutic approaches. Future paradigms will require multiomics profiling, artificial intelligence, and precision medicine to develop mechanism-based diagnostics and individualized treatments, advancing care from symptom-focused to mechanism-targeted approaches.

Cite this article as: Yu C, Wang X, Chen S. The microbiota–gut–brain axis in disorders of gut–brain interaction: Mechanisms and emerging therapeutic strategies. Turk J Gastroenterol. 2026;37(11):1115-1129.

Article Info
Published In
Journal Turkish Journal of Gastroenterology
Volume / Issue Volume 37 · Issue 11
Pages 1115-1129
History
Published Online September 15, 2026
License
Affiliations
Cong Yu ORCID
Department of Gastroenterology, Qingdao Hospital, University of Health and Rehabilitation Sciences (Qingdao Municipal Hospital), Qingdao, China
Xiu Wang ORCID
Department of Obstetrics, Qingdao Hospital, University of Health and Rehabilitation Sciences (Qingdao Municipal Hospital), Qingdao, China
Shuzhu Chen ORCID
Department of Gastroenterology, Qingdao Hospital, University of Health and Rehabilitation Sciences (Qingdao Municipal Hospital), Qingdao, China
Cite this Article
Yu, C., Wang, X., & Chen, S. (2026). The Microbiota–Gut–Brain Axis in Disorders of Gut–Brain Interaction: Mechanisms and Emerging Therapeutic Strategies. Turkish Journal of Gastroenterology, 37(11), 1115–1129. https://doi.org/10.5152/tjg.2026.25517
Outlines